These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 8492013)

  • 1. [Clinical evaluation of tumor-associated trypsin inhibitor (TATI) in benign and malignant gynecological tumor].
    Shigemasa K; Hiura M; Ioka A; Yokoyama T; Nogawa T; Chiba T
    Nihon Sanka Fujinka Gakkai Zasshi; 1993 Mar; 45(3):256-7. PubMed ID: 8492013
    [No Abstract]   [Full Text] [Related]  

  • 2. [Determination of tumor-associated trypsin inhibitor (TATI) in subjects with gastrointestinal diseases. Preliminary data].
    Piantino P; Mosso R; Polloni R; Cerchier A; Gennaretti G; Daziano E
    Minerva Med; 1989 Mar; 80(3):199-203. PubMed ID: 2717042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Significance of the the tumor markers, Ca-125 and tumor-associated trypsin inhibitor in patients with carcinoma of the cervix and uterus].
    Ilić RS; Mihailović D
    Srp Arh Celok Lek; 1992; 120(3-4):97-9. PubMed ID: 1465666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumour-associated trypsin inhibitor, TATI. Clinical use and biological function.
    Stenman UH; Koivunen E; Itkonen O; Turpeinen U; Halila H; Huhtala ML
    Ann Chir Gynaecol; 1989; 78(1):77-82. PubMed ID: 2667452
    [No Abstract]   [Full Text] [Related]  

  • 5. A comparison of the usefulness of serum measurements of CA 125, CA 50 and TATI in patients with malignant and benign gynecological pathology.
    Gadducci A; Ferdeghini M; Facchini V; Ceccarini T; Prontera C; Bianchi R; Fioretti P
    Eur J Gynaecol Oncol; 1990; 11(2):111-5. PubMed ID: 2379509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Fundamental and clinical evaluation of immunoradiometric assay (IRMA) for serum pancreatic oncofetal antigen (POA)].
    Ohba N; Hashimoto T; Nishibu M; Kashiwaya Y; Kawai K; Matsubara F; Miyazaki I
    Rinsho Byori; 1989 Feb; 37(2):153-8. PubMed ID: 2733181
    [No Abstract]   [Full Text] [Related]  

  • 7. Editorial comment on: Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells.
    Schalken J
    Eur Urol; 2007 Dec; 52(6):1679. PubMed ID: 17306439
    [No Abstract]   [Full Text] [Related]  

  • 8. TATI (tumor associated trypsin inhibitor) and cancer antigen 125 (CA 125) in patients with early-stage endometrial cancer.
    Peters-Engl C; Buxbaum P; Ogris E; Sevelda P; Medl M
    Anticancer Res; 1998; 18(6B):4635-9. PubMed ID: 9891532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumour-associated trypsin inhibitor and tumour-associated trypsin.
    Stenman UH
    Scand J Clin Lab Invest Suppl; 1990; 201():93-101. PubMed ID: 2244188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical evaluation of serum CA-50 and CA 19-9 in gynecological tumors].
    Suzuki M; Ohwada M; Tamada T; Sakurabayashi I; Kawai T
    Rinsho Byori; 1989 Jul; 37(7):784-8. PubMed ID: 2558243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum levels of tumor-associated trypsin inhibitor (TATI) in benign and malignant gynecological diseases.
    Torre GC; Rembado R; Barbetti V; Vigliercio GP; Foglia M; Calabrese A; Corongiu F
    Scand J Clin Lab Invest Suppl; 1991; 207():15-8. PubMed ID: 1780684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multivariate analysis of six serum tumor markers (CEA, CA 50, CA 242, TPA, TPS, TATI) and conventional laboratory tests in the diagnosis of hepatopancreatobiliary malignancy.
    Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
    Anticancer Res; 1995; 15(6B):2731-7. PubMed ID: 8669855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Basic and clinical evaluation of pancreatic secretory trypsin inhibitor (PSTI) radioimmunoassay kit].
    Fukushi M; Suzuki K; Kuramoto M; Kondo T; Nogami S; Hara Y; Sakai S; Ookubo A; Tabata I; Onodera T
    Radioisotopes; 1984 May; 33(5):295-8. PubMed ID: 6473842
    [No Abstract]   [Full Text] [Related]  

  • 14. Evaluation of urine tumor-associated trypsin inhibitor, CYFRA 21-1, and urinary bladder cancer antigen for detection of high-grade bladder carcinoma.
    Gkialas I; Papadopoulos G; Iordanidou L; Stathouros G; Tzavara C; Gregorakis A; Lykourinas M
    Urology; 2008 Nov; 72(5):1159-63. PubMed ID: 18514770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pancreatic cancer and tumor markers].
    Watanabe H; Kawakami H; Yamakawa O; Satomura Y; Ohta H; Motoo Y; Okai T; Sawabu N
    Rinsho Byori; 1991 Jun; Suppl 89():58-72. PubMed ID: 1680205
    [No Abstract]   [Full Text] [Related]  

  • 16. [Clinical significance of pancreatic secretory trypsin inhibitor assay as a tumor marker].
    Ogawa M
    Nihon Rinsho; 1990 Feb; 48 Suppl():895-8. PubMed ID: 2355630
    [No Abstract]   [Full Text] [Related]  

  • 17. Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells.
    Paju A; Hotakainen K; Cao Y; Laurila T; Gadaleanu V; Hemminki A; Stenman UH; Bjartell A
    Eur Urol; 2007 Dec; 52(6):1670-9. PubMed ID: 17306443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [CA50].
    Kawabe T
    Nihon Rinsho; 2005 Aug; 63 Suppl 8():645-6. PubMed ID: 16149601
    [No Abstract]   [Full Text] [Related]  

  • 19. Excretion of a tumor-associated trypsin inhibitor (TATI) in urine of patients with gynecological malignancy.
    Huhtala ML; Kahanpää K; Seppälä M; Halila H; Stenman UH
    Int J Cancer; 1983 Jun; 31(6):711-4. PubMed ID: 6190763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparative evaluation of the ability of serum CA 125, CA 19-9, CA 15-3, CA 50, CA 72-4 and TATI assays in reflecting the course of disease in patients with ovarian carcinoma.
    Gadducci A; Ferdeghini M; Ceccarini T; Prontera C; Facchini V; Bianchi R; Fioretti P
    Eur J Gynaecol Oncol; 1990; 11(2):127-33. PubMed ID: 2379512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.